Cobra Biologics and CPI Collaborate on AAV Manufacturing Platform
The collaboration is part of Innovate UK’s competition for the development of regenerative medicines.
Cobra Biologics, an international contract development manufacturing organization (CDMO) of biologics and pharmaceuticals, and the Centre for Process Innovation (CPI), a UK-based technology innovation center, are collaborating on a project focusing on the development of an industrial manufacturing platform for adeno-associated virus (AAV) production, to support gene therapy and regenerative medicine.
Innovate UK, an executive non-departmental public body sponsored by the Department for Business, Innovation, and Skills, has granted £1.4 million in funding to the project, which will cost £1.8 million in total. The project is part of Innovate UK’s competition for the development of regenerative medicines and cell therapies, and is one of five projects that will be funded by an £8-million investment into collaborative R&D projects. These R&D projects address challenges faced by UK companies developing regenerative medicines and cell therapies.
The collaboration between Cobra and CPI will focus on AAV vectors, which are currently the delivery vehicle of choice for gene therapy treatments, according to Cobra Biologics. The proposed collaboration between Cobra and CPI will develop manufacturing process to produce, purify, and characterize a range of AAV vectors.
Source: Cobra Biologics
